Spatial architecture contributes to failure of bulk biomarker-guided neoadjuvant immunotherapy selection in bladder cancer: The DUTRENEO study

Recognizing why bulk tumor markers fail reveals new opportunities to select therapies that actually work.

What the study was

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.